As Mod­er­na rose, Flag­ship cashed in for $1.4B — with a lot more wealth still re­main­ing

2 hours ago
Deals

Damn the crit­ics, Bio­gen CEO Vounatsos or­ders full speed ahead on prep­ping a con­tro­ver­sial ad­u­canum­ab launch as FDA de­ci­sion looms

3 hours ago
Bioregnum
FDA+

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

5 hours ago
People
Financing

UP­DAT­ED: Blue­bird says it has more good news for its gene ther­a­py safe­ty, but a pric­ing dis­agree­ment in Ger­many will spur lay­offs

2 days ago
Cell/Gene Tx

A top an­a­lyst sees Pfiz­er and Mod­er­na seiz­ing a $38B prize as safe­ty frets side­line glob­al vac­cine play­ers

2 days ago
Bioregnum
Coronavirus

UP­DAT­ED: Ver­tex pays CRISPR $900M to take con­trol of sick­le cell part­ner­ship, bet­ting they can beat blue­bird -- and re­new­ing an­a­lyst­s' skep­ti­cism

2 days ago
Deals

Chen Yu jumps ship from Vi­vo Cap­i­tal and goes large, al­ly­ing with The Col­umn Group on an in­au­gur­al $824M biotech crossover fund

2 days ago
Financing
China

Ja­mi Ru­bin, once fa­bled for grilling bio­phar­ma ex­ecs, de­camps to head fi­nance at drug pric­ing dis­rupter

3 days ago
People

FDA lays the ham­mer on Emer­gen­t's Bal­ti­more plant af­ter J&J de­ba­cle, halt­ing all pro­duc­tion in un­usu­al move

3 days ago
R&D
Manufacturing

Till­man Gern­gross' Covid-19 an­ti­body moon­shot scores $336M with the help of new ace CFO. Is an IPO next?

3 days ago
Financing
Coronavirus

Covid-19 vac­cine halt drags on, an FDA ap­point­ment at long last, the great CRO con­sol­i­da­tion, and more

5 days ago
Weekly

As­traZeneca-Alex­ion merg­er slides through FTC re­view af­ter sup­posed M&A crack­down pos­es no bar­ri­ers

6 days ago
Deals
Pharma

J&J faces CDC ad­vi­so­ry com­mit­tee again next week to weigh Covid-19 vac­cine risks

6 days ago
Coronavirus

Opin­ion: Pfiz­er, BioN­Tech did­n't take US gov­ern­men­t's sup­port to de­vel­op their vac­cine. Let's stop rewrit­ing the facts

6 days ago
Opinion

Os­man Kibar lays down his hand at Sa­mumed, step­ping away from CEO role as his once-her­ald­ed an­ti-ag­ing biotech re­brands

6 days ago
Financing

UP­DAT­ED: FDA re­vokes EUA for Eli Lil­ly Covid-19 treat­ment

6 days ago
FDA+
Coronavirus

Ac­tivist in­vestor grabs a multi­bil­lion-pound stake in Glax­o­SmithK­line, trig­ger­ing buzz about a loom­ing show­down at the list­less gi­ant

Last week
Bioregnum
R&D

Glax­o­SmithK­line’s head of vac­cine R&D is jump­ing to a well­ness com­pa­ny con­cen­trat­ing on the mi­cro­bio­me as re­ports of an ex­o­dus start to spread

Last week
People

Mer­ck scraps their $425M Covid-19 drug in lat­est pan­dem­ic set­back

Last week
R&D
Coronavirus

Glax­o­SmithK­line scraps two key mid-stage tri­als for their ICOS drug in the lat­est set­back for the field

Last week
R&D

Af­ter be­ing goad­ed to sell the com­pa­ny, Alex­ion's CEO set some am­bi­tious new goals for in­vestors. Then Pas­cal So­ri­ot came call­ing

Last week
Deals

Pankaj Bhar­ga­va was a cen­tral fig­ure in the group fash­ion­ing Gilead’s on­col­o­gy strat­e­gy. Now he’s jumped to the VC side and the next-gen game at Dana-Far­ber

Last week
People

Tim Lu’s gene-cir­cuit star Sen­ti signs up for a $645M dis­cov­ery al­liance with Roche sub Spark

Last week
Deals

Bain dou­bles down on Tony Coles’ quest to get a late-stage Parkin­son’s drug through to mar­ket

Last week
Financing
R&D
1234 Next page Last page